# Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours

> **NCT05114668** · PHASE1 · COMPLETED · sponsor: **Kazia Therapeutics Limited** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** EVT801

## Key facts

- **NCT ID:** NCT05114668
- **Lead sponsor:** Kazia Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-03
- **Primary completion:** 2024-11-04
- **Final completion:** 2024-11-22
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05114668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05114668, "Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05114668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*